Savant Capital, LLC Lexicon Pharmaceuticals, Inc. Transaction History
Savant Capital, LLC
- $15.3 Billion
- Q2 2025
A detailed history of Savant Capital, LLC transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Savant Capital, LLC holds 69,578 shares of LXRX stock, worth $75,144. This represents 0.0% of its overall portfolio holdings.
Number of Shares
69,578
Previous 52,230
33.21%
Holding current value
$75,144
Previous $24,000
175.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding LXRX
# of Institutions
133Shares Held
196MCall Options Held
310KPut Options Held
77.3K-
Artal Group S.A. Luxembourg, N4136MShares$147 Million100.0% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$10.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.85MShares$9.56 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY8.21MShares$8.87 Million0.03% of portfolio
-
Siren, L.L.C. New York, NY3.52MShares$3.8 Million0.09% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $204M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...